Global Biosimilars Market Research Report 2024 - Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2031
ReportID: 542221
|
Published Date: 2024/07/06
|
No. of Pages: 165
|
Categories: Life Sciences
|
Format : 
The global Biosimilars market was valued at 4843.02 Million USD in 2020 and will grow with a CAGR of 18.83% from 2020 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
A biosimilar is a biologic medical product highly similar to another already approved biological medicine (the `reference medicine`). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product`s patent expires. Reference to the innovator product is an integral component of the approval.
By Market Verdors:
Pfizer
Novartis
Biocon
Biogen
Fresenius Kabi AG
Boehringer Ingelheim
Merck KgaA
Mylan
Eli Lilly
Teva Pharmaceutical
Dr. Reddys Laboratories
Amgen
Celltrion
Samsung Biologics
Roche
Probiomed
Apotex
Chong Kun Dang
JCR Pharmaceuticals
Gan & Lee Pharmaceuticals
Gedeon Richter
Biocad
Coherus Bioscience
Stada Arzneimittel AG
By Types:
Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Recombinant Glycosylated Proteins
By Applications:
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
A biosimilar is a biologic medical product highly similar to another already approved biological medicine (the `reference medicine`). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product`s patent expires. Reference to the innovator product is an integral component of the approval.
By Market Verdors:
Pfizer
Novartis
Biocon
Biogen
Fresenius Kabi AG
Boehringer Ingelheim
Merck KgaA
Mylan
Eli Lilly
Teva Pharmaceutical
Dr. Reddys Laboratories
Amgen
Celltrion
Samsung Biologics
Roche
Probiomed
Apotex
Chong Kun Dang
JCR Pharmaceuticals
Gan & Lee Pharmaceuticals
Gedeon Richter
Biocad
Coherus Bioscience
Stada Arzneimittel AG
By Types:
Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon)
Recombinant Glycosylated Proteins
By Applications:
Oncology
Blood Disorders
Growth Hormonal Deficiency
Chronic and Autoimmune Disorders
Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2022-2027)
1.4.2 East Asia Market States and Outlook (2022-2027)
1.4.3 Europe Market States and Outlook (2022-2027)
1.4.4 South Asia Market States and Outlook (2022-2027)
1.4.5 Southeast Asia Market States and Outlook (2022-2027)
1.4.6 Middle East Market States and Outlook (2022-2027)
1.4.7 Africa Market States and Outlook (2022-2027)
1.4.8 Oceania Market States and Outlook (2022-2027)
1.4.9 South America Market States and Outlook (2022-2027)
1.5 Global Biosimilars Market Size Analysis from 2022 to 2027
1.5.1 Global Biosimilars Market Size Analysis from 2022 to 2027 by Consumption Volume
1.5.2 Global Biosimilars Market Size Analysis from 2022 to 2027 by Value
1.5.3 Global Biosimilars Price Trends Analysis from 2022 to 2027
1.6 COVID-19 Outbreak: Biosimilars Industry Impact
Chapter 2 Global Biosimilars Competition by Types, Applications, and Top Regions and Countries
2.1 Global Biosimilars (Volume and Value) by Type
2.1.1 Global Biosimilars Consumption and Market Share by Type (2016-2021)
2.1.2 Global Biosimilars Revenue and Market Share by Type (2016-2021)
2.2 Global Biosimilars (Volume and Value) by Application
2.2.1 Global Biosimilars Consumption and Market Share by Application (2016-2021)
2.2.2 Global Biosimilars Revenue and Market Share by Application (2016-2021)
2.3 Global Biosimilars (Volume and Value) by Regions
2.3.1 Global Biosimilars Consumption and Market Share by Regions (2016-2021)
2.3.2 Global Biosimilars Revenue and Market Share by Regions (2016-2021)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2016-2021 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2016-2021 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Biosimilars Sales, Consumption, Export, Import by Regions (2016-2021)
4.1 Global Biosimilars Consumption by Regions (2016-2021)
4.2 North America Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.3 East Asia Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.4 Europe Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.5 South Asia Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.6 Southeast Asia Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.7 Middle East Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.8 Africa Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.9 Oceania Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.10 South America Biosimilars Sales, Consumption, Export, Import (2016-2021)
Chapter 5 North America Biosimilars Market Analysis
5.1 North America Biosimilars Consumption and Value Analysis
5.1.1 North America Biosimilars Market Under COVID-19
5.2 North America Biosimilars Consumption Volume by Types
5.3 North America Biosimilars Consumption Structure by Application
5.4 North America Biosimilars Consumption by Top Countries
5.4.1 United States Biosimilars Consumption Volume from 2016 to 2021
5.4.2 Canada Biosimilars Consumption Volume from 2016 to 2021
5.4.3 Mexico Biosimilars Consumption Volume from 2016 to 2021
Chapter 6 East Asia Biosimilars Market Analysis
6.1 East Asia Biosimilars Consumption and Value Analysis
6.1.1 East Asia Biosimilars Market Under COVID-19
6.2 East Asia Biosimilars Consumption Volume by Types
6.3 East Asia Biosimilars Consumption Structure by Application
6.4 East Asia Biosimilars Consumption by Top Countries
6.4.1 China Biosimilars Consumption Volume from 2016 to 2021
6.4.2 Japan Biosimilars Consumption Volume from 2016 to 2021
6.4.3 South Korea Biosimilars Consumption Volume from 2016 to 2021
Chapter 7 Europe Biosimilars Market Analysis
7.1 Europe Biosimilars Consumption and Value Analysis
7.1.1 Europe Biosimilars Market Under COVID-19
7.2 Europe Biosimilars Consumption Volume by Types
7.3 Europe Biosimilars Consumption Structure by Application
7.4 Europe Biosimilars Consumption by Top Countries
7.4.1 Germany Biosimilars Consumption Volume from 2016 to 2021
7.4.2 UK Biosimilars Consumption Volume from 2016 to 2021
7.4.3 France Biosimilars Consumption Volume from 2016 to 2021
7.4.4 Italy Biosimilars Consumption Volume from 2016 to 2021
7.4.5 Russia Biosimilars Consumption Volume from 2016 to 2021
7.4.6 Spain Biosimilars Consumption Volume from 2016 to 2021
7.4.7 Netherlands Biosimilars Consumption Volume from 2016 to 2021
7.4.8 Switzerland Biosimilars Consumption Volume from 2016 to 2021
7.4.9 Poland Biosimilars Consumption Volume from 2016 to 2021
Chapter 8 South Asia Biosimilars Market Analysis
8.1 South Asia Biosimilars Consumption and Value Analysis
8.1.1 South Asia Biosimilars Market Under COVID-19
8.2 South Asia Biosimilars Consumption Volume by Types
8.3 South Asia Biosimilars Consumption Structure by Application
8.4 South Asia Biosimilars Consumption by Top Countries
8.4.1 India Biosimilars Consumption Volume from 2016 to 2021
8.4.2 Pakistan Biosimilars Consumption Volume from 2016 to 2021
8.4.3 Bangladesh Biosimilars Consumption Volume from 2016 to 2021
Chapter 9 Southeast Asia Biosimilars Market Analysis
9.1 Southeast Asia Biosimilars Consumption and Value Analysis
9.1.1 Southeast Asia Biosimilars Market Under COVID-19
9.2 Southeast Asia Biosimilars Consumption Volume by Types
9.3 Southeast Asia Biosimilars Consumption Structure by Application
9.4 Southeast Asia Biosimilars Consumption by Top Countries
9.4.1 Indonesia Biosimilars Consumption Volume from 2016 to 2021
9.4.2 Thailand Biosimilars Consumption Volume from 2016 to 2021
9.4.3 Singapore Biosimilars Consumption Volume from 2016 to 2021
9.4.4 Malaysia Biosimilars Consumption Volume from 2016 to 2021
9.4.5 Philippines Biosimilars Consumption Volume from 2016 to 2021
9.4.6 Vietnam Biosimilars Consumption Volume from 2016 to 2021
9.4.7 Myanmar Biosimilars Consumption Volume from 2016 to 2021
Chapter 10 Middle East Biosimilars Market Analysis
10.1 Middle East Biosimilars Consumption and Value Analysis
10.1.1 Middle East Biosimilars Market Under COVID-19
10.2 Middle East Biosimilars Consumption Volume by Types
10.3 Middle East Biosimilars Consumption Structure by Application
10.4 Middle East Biosimilars Consumption by Top Countries
10.4.1 Turkey Biosimilars Consumption Volume from 2016 to 2021
10.4.2 Saudi Arabia Biosimilars Consumption Volume from 2016 to 2021
10.4.3 Iran Biosimilars Consumption Volume from 2016 to 2021
10.4.4 United Arab Emirates Biosimilars Consumption Volume from 2016 to 2021
10.4.5 Israel Biosimilars Consumption Volume from 2016 to 2021
10.4.6 Iraq Biosimilars Consumption Volume from 2016 to 2021
10.4.7 Qatar Biosimilars Consumption Volume from 2016 to 2021
10.4.8 Kuwait Biosimilars Consumption Volume from 2016 to 2021
10.4.9 Oman Biosimilars Consumption Volume from 2016 to 2021
Chapter 11 Africa Biosimilars Market Analysis
11.1 Africa Biosimilars Consumption and Value Analysis
11.1.1 Africa Biosimilars Market Under COVID-19
11.2 Africa Biosimilars Consumption Volume by Types
11.3 Africa Biosimilars Consumption Structure by Application
11.4 Africa Biosimilars Consumption by Top Countries
11.4.1 Nigeria Biosimilars Consumption Volume from 2016 to 2021
11.4.2 South Africa Biosimilars Consumption Volume from 2016 to 2021
11.4.3 Egypt Biosimilars Consumption Volume from 2016 to 2021
11.4.4 Algeria Biosimilars Consumption Volume from 2016 to 2021
11.4.5 Morocco Biosimilars Consumption Volume from 2016 to 2021
Chapter 12 Oceania Biosimilars Market Analysis
12.1 Oceania Biosimilars Consumption and Value Analysis
12.2 Oceania Biosimilars Consumption Volume by Types
12.3 Oceania Biosimilars Consumption Structure by Application
12.4 Oceania Biosimilars Consumption by Top Countries
12.4.1 Australia Biosimilars Consumption Volume from 2016 to 2021
12.4.2 New Zealand Biosimilars Consumption Volume from 2016 to 2021
Chapter 13 South America Biosimilars Market Analysis
13.1 South America Biosimilars Consumption and Value Analysis
13.1.1 South America Biosimilars Market Under COVID-19
13.2 South America Biosimilars Consumption Volume by Types
13.3 South America Biosimilars Consumption Structure by Application
13.4 South America Biosimilars Consumption Volume by Major Countries
13.4.1 Brazil Biosimilars Consumption Volume from 2016 to 2021
13.4.2 Argentina Biosimilars Consumption Volume from 2016 to 2021
13.4.3 Columbia Biosimilars Consumption Volume from 2016 to 2021
13.4.4 Chile Biosimilars Consumption Volume from 2016 to 2021
13.4.5 Venezuela Biosimilars Consumption Volume from 2016 to 2021
13.4.6 Peru Biosimilars Consumption Volume from 2016 to 2021
13.4.7 Puerto Rico Biosimilars Consumption Volume from 2016 to 2021
13.4.8 Ecuador Biosimilars Consumption Volume from 2016 to 2021
Chapter 14 Company Profiles and Key Figures in Biosimilars Business
14.1 Pfizer
14.1.1 Pfizer Company Profile
14.1.2 Pfizer Biosimilars Product Specification
14.1.3 Pfizer Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.2 Novartis
14.2.1 Novartis Company Profile
14.2.2 Novartis Biosimilars Product Specification
14.2.3 Novartis Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.3 Biocon
14.3.1 Biocon Company Profile
14.3.2 Biocon Biosimilars Product Specification
14.3.3 Biocon Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.4 Biogen
14.4.1 Biogen Company Profile
14.4.2 Biogen Biosimilars Product Specification
14.4.3 Biogen Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.5 Fresenius Kabi AG
14.5.1 Fresenius Kabi AG Company Profile
14.5.2 Fresenius Kabi AG Biosimilars Product Specification
14.5.3 Fresenius Kabi AG Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.6 Boehringer Ingelheim
14.6.1 Boehringer Ingelheim Company Profile
14.6.2 Boehringer Ingelheim Biosimilars Product Specification
14.6.3 Boehringer Ingelheim Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.7 Merck KgaA
14.7.1 Merck KgaA Company Profile
14.7.2 Merck KgaA Biosimilars Product Specification
14.7.3 Merck KgaA Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.8 Mylan
14.8.1 Mylan Company Profile
14.8.2 Mylan Biosimilars Product Specification
14.8.3 Mylan Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.9 Eli Lilly
14.9.1 Eli Lilly Company Profile
14.9.2 Eli Lilly Biosimilars Product Specification
14.9.3 Eli Lilly Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.10 Teva Pharmaceutical
14.10.1 Teva Pharmaceutical Company Profile
14.10.2 Teva Pharmaceutical Biosimilars Product Specification
14.10.3 Teva Pharmaceutical Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.11 Dr. Reddys Laboratories
14.11.1 Dr. Reddys Laboratories Company Profile
14.11.2 Dr. Reddys Laboratories Biosimilars Product Specification
14.11.3 Dr. Reddys Laboratories Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.12 Amgen
14.12.1 Amgen Company Profile
14.12.2 Amgen Biosimilars Product Specification
14.12.3 Amgen Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.13 Celltrion
14.13.1 Celltrion Company Profile
14.13.2 Celltrion Biosimilars Product Specification
14.13.3 Celltrion Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.14 Samsung Biologics
14.14.1 Samsung Biologics Company Profile
14.14.2 Samsung Biologics Biosimilars Product Specification
14.14.3 Samsung Biologics Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.15 Roche
14.15.1 Roche Company Profile
14.15.2 Roche Biosimilars Product Specification
14.15.3 Roche Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.16 Probiomed
14.16.1 Probiomed Company Profile
14.16.2 Probiomed Biosimilars Product Specification
14.16.3 Probiomed Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.17 Apotex
14.17.1 Apotex Company Profile
14.17.2 Apotex Biosimilars Product Specification
14.17.3 Apotex Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.18 Chong Kun Dang
14.18.1 Chong Kun Dang Company Profile
14.18.2 Chong Kun Dang Biosimilars Product Specification
14.18.3 Chong Kun Dang Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.19 JCR Pharmaceuticals
14.19.1 JCR Pharmaceuticals Company Profile
14.19.2 JCR Pharmaceuticals Biosimilars Product Specification
14.19.3 JCR Pharmaceuticals Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.20 Gan & Lee Pharmaceuticals
14.20.1 Gan & Lee Pharmaceuticals Company Profile
14.20.2 Gan & Lee Pharmaceuticals Biosimilars Product Specification
14.20.3 Gan & Lee Pharmaceuticals Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.21 Gedeon Richter
14.21.1 Gedeon Richter Company Profile
14.21.2 Gedeon Richter Biosimilars Product Specification
14.21.3 Gedeon Richter Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.22 Biocad
14.22.1 Biocad Company Profile
14.22.2 Biocad Biosimilars Product Specification
14.22.3 Biocad Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.23 Coherus Bioscience
14.23.1 Coherus Bioscience Company Profile
14.23.2 Coherus Bioscience Biosimilars Product Specification
14.23.3 Coherus Bioscience Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.24 Stada Arzneimittel AG
14.24.1 Stada Arzneimittel AG Company Profile
14.24.2 Stada Arzneimittel AG Biosimilars Product Specification
14.24.3 Stada Arzneimittel AG Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
Chapter 15 Global Biosimilars Market Forecast (2022-2027)
15.1 Global Biosimilars Consumption Volume, Revenue and Price Forecast (2022-2027)
15.1.1 Global Biosimilars Consumption Volume and Growth Rate Forecast (2022-2027)
15.1.2 Global Biosimilars Value and Growth Rate Forecast (2022-2027)
15.2 Global Biosimilars Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)
15.2.1 Global Biosimilars Consumption Volume and Growth Rate Forecast by Regions (2022-2027)
15.2.2 Global Biosimilars Value and Growth Rate Forecast by Regions (2022-2027)
15.2.3 North America Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.4 East Asia Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.5 Europe Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.6 South Asia Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.7 Southeast Asia Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.8 Middle East Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.9 Africa Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.10 Oceania Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.11 South America Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.3 Global Biosimilars Consumption Volume, Revenue and Price Forecast by Type (2022-2027)
15.3.1 Global Biosimilars Consumption Forecast by Type (2022-2027)
15.3.2 Global Biosimilars Revenue Forecast by Type (2022-2027)
15.3.3 Global Biosimilars Price Forecast by Type (2022-2027)
15.4 Global Biosimilars Consumption Volume Forecast by Application (2022-2027)
15.5 Biosimilars Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2022-2027)
1.4.2 East Asia Market States and Outlook (2022-2027)
1.4.3 Europe Market States and Outlook (2022-2027)
1.4.4 South Asia Market States and Outlook (2022-2027)
1.4.5 Southeast Asia Market States and Outlook (2022-2027)
1.4.6 Middle East Market States and Outlook (2022-2027)
1.4.7 Africa Market States and Outlook (2022-2027)
1.4.8 Oceania Market States and Outlook (2022-2027)
1.4.9 South America Market States and Outlook (2022-2027)
1.5 Global Biosimilars Market Size Analysis from 2022 to 2027
1.5.1 Global Biosimilars Market Size Analysis from 2022 to 2027 by Consumption Volume
1.5.2 Global Biosimilars Market Size Analysis from 2022 to 2027 by Value
1.5.3 Global Biosimilars Price Trends Analysis from 2022 to 2027
1.6 COVID-19 Outbreak: Biosimilars Industry Impact
Chapter 2 Global Biosimilars Competition by Types, Applications, and Top Regions and Countries
2.1 Global Biosimilars (Volume and Value) by Type
2.1.1 Global Biosimilars Consumption and Market Share by Type (2016-2021)
2.1.2 Global Biosimilars Revenue and Market Share by Type (2016-2021)
2.2 Global Biosimilars (Volume and Value) by Application
2.2.1 Global Biosimilars Consumption and Market Share by Application (2016-2021)
2.2.2 Global Biosimilars Revenue and Market Share by Application (2016-2021)
2.3 Global Biosimilars (Volume and Value) by Regions
2.3.1 Global Biosimilars Consumption and Market Share by Regions (2016-2021)
2.3.2 Global Biosimilars Revenue and Market Share by Regions (2016-2021)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2016-2021 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2016-2021 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Biosimilars Sales, Consumption, Export, Import by Regions (2016-2021)
4.1 Global Biosimilars Consumption by Regions (2016-2021)
4.2 North America Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.3 East Asia Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.4 Europe Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.5 South Asia Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.6 Southeast Asia Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.7 Middle East Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.8 Africa Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.9 Oceania Biosimilars Sales, Consumption, Export, Import (2016-2021)
4.10 South America Biosimilars Sales, Consumption, Export, Import (2016-2021)
Chapter 5 North America Biosimilars Market Analysis
5.1 North America Biosimilars Consumption and Value Analysis
5.1.1 North America Biosimilars Market Under COVID-19
5.2 North America Biosimilars Consumption Volume by Types
5.3 North America Biosimilars Consumption Structure by Application
5.4 North America Biosimilars Consumption by Top Countries
5.4.1 United States Biosimilars Consumption Volume from 2016 to 2021
5.4.2 Canada Biosimilars Consumption Volume from 2016 to 2021
5.4.3 Mexico Biosimilars Consumption Volume from 2016 to 2021
Chapter 6 East Asia Biosimilars Market Analysis
6.1 East Asia Biosimilars Consumption and Value Analysis
6.1.1 East Asia Biosimilars Market Under COVID-19
6.2 East Asia Biosimilars Consumption Volume by Types
6.3 East Asia Biosimilars Consumption Structure by Application
6.4 East Asia Biosimilars Consumption by Top Countries
6.4.1 China Biosimilars Consumption Volume from 2016 to 2021
6.4.2 Japan Biosimilars Consumption Volume from 2016 to 2021
6.4.3 South Korea Biosimilars Consumption Volume from 2016 to 2021
Chapter 7 Europe Biosimilars Market Analysis
7.1 Europe Biosimilars Consumption and Value Analysis
7.1.1 Europe Biosimilars Market Under COVID-19
7.2 Europe Biosimilars Consumption Volume by Types
7.3 Europe Biosimilars Consumption Structure by Application
7.4 Europe Biosimilars Consumption by Top Countries
7.4.1 Germany Biosimilars Consumption Volume from 2016 to 2021
7.4.2 UK Biosimilars Consumption Volume from 2016 to 2021
7.4.3 France Biosimilars Consumption Volume from 2016 to 2021
7.4.4 Italy Biosimilars Consumption Volume from 2016 to 2021
7.4.5 Russia Biosimilars Consumption Volume from 2016 to 2021
7.4.6 Spain Biosimilars Consumption Volume from 2016 to 2021
7.4.7 Netherlands Biosimilars Consumption Volume from 2016 to 2021
7.4.8 Switzerland Biosimilars Consumption Volume from 2016 to 2021
7.4.9 Poland Biosimilars Consumption Volume from 2016 to 2021
Chapter 8 South Asia Biosimilars Market Analysis
8.1 South Asia Biosimilars Consumption and Value Analysis
8.1.1 South Asia Biosimilars Market Under COVID-19
8.2 South Asia Biosimilars Consumption Volume by Types
8.3 South Asia Biosimilars Consumption Structure by Application
8.4 South Asia Biosimilars Consumption by Top Countries
8.4.1 India Biosimilars Consumption Volume from 2016 to 2021
8.4.2 Pakistan Biosimilars Consumption Volume from 2016 to 2021
8.4.3 Bangladesh Biosimilars Consumption Volume from 2016 to 2021
Chapter 9 Southeast Asia Biosimilars Market Analysis
9.1 Southeast Asia Biosimilars Consumption and Value Analysis
9.1.1 Southeast Asia Biosimilars Market Under COVID-19
9.2 Southeast Asia Biosimilars Consumption Volume by Types
9.3 Southeast Asia Biosimilars Consumption Structure by Application
9.4 Southeast Asia Biosimilars Consumption by Top Countries
9.4.1 Indonesia Biosimilars Consumption Volume from 2016 to 2021
9.4.2 Thailand Biosimilars Consumption Volume from 2016 to 2021
9.4.3 Singapore Biosimilars Consumption Volume from 2016 to 2021
9.4.4 Malaysia Biosimilars Consumption Volume from 2016 to 2021
9.4.5 Philippines Biosimilars Consumption Volume from 2016 to 2021
9.4.6 Vietnam Biosimilars Consumption Volume from 2016 to 2021
9.4.7 Myanmar Biosimilars Consumption Volume from 2016 to 2021
Chapter 10 Middle East Biosimilars Market Analysis
10.1 Middle East Biosimilars Consumption and Value Analysis
10.1.1 Middle East Biosimilars Market Under COVID-19
10.2 Middle East Biosimilars Consumption Volume by Types
10.3 Middle East Biosimilars Consumption Structure by Application
10.4 Middle East Biosimilars Consumption by Top Countries
10.4.1 Turkey Biosimilars Consumption Volume from 2016 to 2021
10.4.2 Saudi Arabia Biosimilars Consumption Volume from 2016 to 2021
10.4.3 Iran Biosimilars Consumption Volume from 2016 to 2021
10.4.4 United Arab Emirates Biosimilars Consumption Volume from 2016 to 2021
10.4.5 Israel Biosimilars Consumption Volume from 2016 to 2021
10.4.6 Iraq Biosimilars Consumption Volume from 2016 to 2021
10.4.7 Qatar Biosimilars Consumption Volume from 2016 to 2021
10.4.8 Kuwait Biosimilars Consumption Volume from 2016 to 2021
10.4.9 Oman Biosimilars Consumption Volume from 2016 to 2021
Chapter 11 Africa Biosimilars Market Analysis
11.1 Africa Biosimilars Consumption and Value Analysis
11.1.1 Africa Biosimilars Market Under COVID-19
11.2 Africa Biosimilars Consumption Volume by Types
11.3 Africa Biosimilars Consumption Structure by Application
11.4 Africa Biosimilars Consumption by Top Countries
11.4.1 Nigeria Biosimilars Consumption Volume from 2016 to 2021
11.4.2 South Africa Biosimilars Consumption Volume from 2016 to 2021
11.4.3 Egypt Biosimilars Consumption Volume from 2016 to 2021
11.4.4 Algeria Biosimilars Consumption Volume from 2016 to 2021
11.4.5 Morocco Biosimilars Consumption Volume from 2016 to 2021
Chapter 12 Oceania Biosimilars Market Analysis
12.1 Oceania Biosimilars Consumption and Value Analysis
12.2 Oceania Biosimilars Consumption Volume by Types
12.3 Oceania Biosimilars Consumption Structure by Application
12.4 Oceania Biosimilars Consumption by Top Countries
12.4.1 Australia Biosimilars Consumption Volume from 2016 to 2021
12.4.2 New Zealand Biosimilars Consumption Volume from 2016 to 2021
Chapter 13 South America Biosimilars Market Analysis
13.1 South America Biosimilars Consumption and Value Analysis
13.1.1 South America Biosimilars Market Under COVID-19
13.2 South America Biosimilars Consumption Volume by Types
13.3 South America Biosimilars Consumption Structure by Application
13.4 South America Biosimilars Consumption Volume by Major Countries
13.4.1 Brazil Biosimilars Consumption Volume from 2016 to 2021
13.4.2 Argentina Biosimilars Consumption Volume from 2016 to 2021
13.4.3 Columbia Biosimilars Consumption Volume from 2016 to 2021
13.4.4 Chile Biosimilars Consumption Volume from 2016 to 2021
13.4.5 Venezuela Biosimilars Consumption Volume from 2016 to 2021
13.4.6 Peru Biosimilars Consumption Volume from 2016 to 2021
13.4.7 Puerto Rico Biosimilars Consumption Volume from 2016 to 2021
13.4.8 Ecuador Biosimilars Consumption Volume from 2016 to 2021
Chapter 14 Company Profiles and Key Figures in Biosimilars Business
14.1 Pfizer
14.1.1 Pfizer Company Profile
14.1.2 Pfizer Biosimilars Product Specification
14.1.3 Pfizer Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.2 Novartis
14.2.1 Novartis Company Profile
14.2.2 Novartis Biosimilars Product Specification
14.2.3 Novartis Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.3 Biocon
14.3.1 Biocon Company Profile
14.3.2 Biocon Biosimilars Product Specification
14.3.3 Biocon Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.4 Biogen
14.4.1 Biogen Company Profile
14.4.2 Biogen Biosimilars Product Specification
14.4.3 Biogen Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.5 Fresenius Kabi AG
14.5.1 Fresenius Kabi AG Company Profile
14.5.2 Fresenius Kabi AG Biosimilars Product Specification
14.5.3 Fresenius Kabi AG Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.6 Boehringer Ingelheim
14.6.1 Boehringer Ingelheim Company Profile
14.6.2 Boehringer Ingelheim Biosimilars Product Specification
14.6.3 Boehringer Ingelheim Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.7 Merck KgaA
14.7.1 Merck KgaA Company Profile
14.7.2 Merck KgaA Biosimilars Product Specification
14.7.3 Merck KgaA Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.8 Mylan
14.8.1 Mylan Company Profile
14.8.2 Mylan Biosimilars Product Specification
14.8.3 Mylan Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.9 Eli Lilly
14.9.1 Eli Lilly Company Profile
14.9.2 Eli Lilly Biosimilars Product Specification
14.9.3 Eli Lilly Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.10 Teva Pharmaceutical
14.10.1 Teva Pharmaceutical Company Profile
14.10.2 Teva Pharmaceutical Biosimilars Product Specification
14.10.3 Teva Pharmaceutical Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.11 Dr. Reddys Laboratories
14.11.1 Dr. Reddys Laboratories Company Profile
14.11.2 Dr. Reddys Laboratories Biosimilars Product Specification
14.11.3 Dr. Reddys Laboratories Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.12 Amgen
14.12.1 Amgen Company Profile
14.12.2 Amgen Biosimilars Product Specification
14.12.3 Amgen Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.13 Celltrion
14.13.1 Celltrion Company Profile
14.13.2 Celltrion Biosimilars Product Specification
14.13.3 Celltrion Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.14 Samsung Biologics
14.14.1 Samsung Biologics Company Profile
14.14.2 Samsung Biologics Biosimilars Product Specification
14.14.3 Samsung Biologics Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.15 Roche
14.15.1 Roche Company Profile
14.15.2 Roche Biosimilars Product Specification
14.15.3 Roche Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.16 Probiomed
14.16.1 Probiomed Company Profile
14.16.2 Probiomed Biosimilars Product Specification
14.16.3 Probiomed Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.17 Apotex
14.17.1 Apotex Company Profile
14.17.2 Apotex Biosimilars Product Specification
14.17.3 Apotex Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.18 Chong Kun Dang
14.18.1 Chong Kun Dang Company Profile
14.18.2 Chong Kun Dang Biosimilars Product Specification
14.18.3 Chong Kun Dang Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.19 JCR Pharmaceuticals
14.19.1 JCR Pharmaceuticals Company Profile
14.19.2 JCR Pharmaceuticals Biosimilars Product Specification
14.19.3 JCR Pharmaceuticals Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.20 Gan & Lee Pharmaceuticals
14.20.1 Gan & Lee Pharmaceuticals Company Profile
14.20.2 Gan & Lee Pharmaceuticals Biosimilars Product Specification
14.20.3 Gan & Lee Pharmaceuticals Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.21 Gedeon Richter
14.21.1 Gedeon Richter Company Profile
14.21.2 Gedeon Richter Biosimilars Product Specification
14.21.3 Gedeon Richter Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.22 Biocad
14.22.1 Biocad Company Profile
14.22.2 Biocad Biosimilars Product Specification
14.22.3 Biocad Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.23 Coherus Bioscience
14.23.1 Coherus Bioscience Company Profile
14.23.2 Coherus Bioscience Biosimilars Product Specification
14.23.3 Coherus Bioscience Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.24 Stada Arzneimittel AG
14.24.1 Stada Arzneimittel AG Company Profile
14.24.2 Stada Arzneimittel AG Biosimilars Product Specification
14.24.3 Stada Arzneimittel AG Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
Chapter 15 Global Biosimilars Market Forecast (2022-2027)
15.1 Global Biosimilars Consumption Volume, Revenue and Price Forecast (2022-2027)
15.1.1 Global Biosimilars Consumption Volume and Growth Rate Forecast (2022-2027)
15.1.2 Global Biosimilars Value and Growth Rate Forecast (2022-2027)
15.2 Global Biosimilars Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)
15.2.1 Global Biosimilars Consumption Volume and Growth Rate Forecast by Regions (2022-2027)
15.2.2 Global Biosimilars Value and Growth Rate Forecast by Regions (2022-2027)
15.2.3 North America Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.4 East Asia Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.5 Europe Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.6 South Asia Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.7 Southeast Asia Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.8 Middle East Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.9 Africa Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.10 Oceania Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.11 South America Biosimilars Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.3 Global Biosimilars Consumption Volume, Revenue and Price Forecast by Type (2022-2027)
15.3.1 Global Biosimilars Consumption Forecast by Type (2022-2027)
15.3.2 Global Biosimilars Revenue Forecast by Type (2022-2027)
15.3.3 Global Biosimilars Price Forecast by Type (2022-2027)
15.4 Global Biosimilars Consumption Volume Forecast by Application (2022-2027)
15.5 Biosimilars Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
Published On:2024/07/06
Base Year:
Historical Data:
No of Pages:165
Price
Global Biosimilars Market Research Report 2024 - Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2031
A2Z Market Research is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends.
Subscribe Us
Sign up today for tips and latest news
and exclusive special offers.
